medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2012, Number 1

<< Back Next >>

Ann Hepatol 2012; 11 (1)

Hepatic dysfunction in children with tuberculosis on treatment with antituberculous therapy

Mansukhani S, Shah I

Language: English
References: 22
Page: 96-99
PDF size: 71.87 Kb.


ABSTRACT

Aim. To determine the incidence and factors associated with drug induced hepatic dysfunction in children on anti-tuberculous treatment (ATT). Setting. Pediatric Tuberculosis Clinic at B.J. Wadia Children’s Hospital, Mumbai. Material and methods. 46 children with tuberculosis on ATT between April 2007 and February 2008 were included. Serum glutamic pyruvic transaminase (SGPT) level was measured at the beginning, after 15 days of starting ATT, at the end intensive phase and then if the patient developed symptoms of hepatic dysfunction. A value 3 times the normal value of the testing laboratory was considered to be significant for liver dysfunction. Liver dysfunction was analysed for association with factors like age, sex, weight, malnutrition, type of tuberculosis and severity of tuberculosis using SPSS Statistics software, Version15.0. Results. Seven (15.2 %) out of 46 children developed drug induced hepatic dysfunction, of which 2 (28.6%) patients had 2 episodes of liver dysfunction while 5 (71.4%) had 1 episode of liver dysfunction. One (14.3%) developed symptom of hepatitis in the form of jaundice and hepatomegaly. All the patients developing liver dysfunction were in the intensive phase of treatment. The mean age of the children developing liver dysfunction was 4.0 ± 3.76 years. Liver dysfunction was associated with age younger than 3½ years (p = 0.025). Liver dysfunction was not associated with sex, weight, malnutrition, type of tuberculosis and severity of tuberculosis. Conclusion. Regular monitoring of SGPT levels is recommended in all children on ATT below the age of 3 ½ years.


REFERENCES

  1. Black M, Mitchell JR, Zimmerman HJ, Ishak KG, Epler GR. Isoniazid-associated hepatitis in 114 patients. Gastroenterology 1975; 69: 289-302.

  2. Agal S, Baijal R, Pramanik S, Patel N, Gupte P, Kamani P, et al. Monitoring and management of antituberculosis drug induced hepatotoxicity. J Gastroenterol Hepatol 2005; 20: 1745-52.

  3. Yee D, Valiquette C, Pelletier M, Parisien I, Rocher I, Menzies D. Incidence of serious side effects from firstline antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med 2003; 167: 1472-7.

  4. Weisiger RA. Isoniazid Hepatotoxicity. [Online] 2007 Jun 21; Available from: URL:http://emedicine.medscape.com/ article/180554-overview

  5. Ohkawa K, Hashiguchi M, Ohno K, Kiuchi C, Takahashi S, Kondo S, et al. Risk factors for antituberculous chemotherapy- induced hepatotoxicity in Japanese pediatric patients. Clin Pharmacol Ther 2002; 72: 220-6.

  6. Gendrel D, Nardou M, Mouba JF, Gahouma D, Moussavou A, Boguikouma JB. Hepatotoxicity of the combination of isoniazid- rifampicin in African children. Role of malnutrition and HB virus. Arch Fr Pediatr 1989; 46: 645-8.

  7. Consensus Statement of IAP Working Group. Treatment of childhood tuberculosis: Indian Academy of Pediatrics. Indian Pediatr 1997; 34: 1093-6.

  8. Chopra K. Short course chemotherapy in childhood tuberculosis. Indian Pediatr 1995; 32: 625-8.

  9. Khadilkar VV, Khadilkar AV, Choudhury P, Agarwal KN, Ugra D, Shah NK. IAP growth monitoring guidelines for children from birth to 18 years. Indian Pediatr 2007; 44: 187-97.

  10. Corrigan D, Paton J. Hepatic enzyme abnormalities in children on triple therapy for tuberculosis. Pediatr Pulmonol 1999; 27: 37-42.

  11. Kabra SK, Lodha R, Seth V. Category based treatment of tuberculosis in children. Indian Pediatr 2004; 41: 927-37.

  12. Tsagaropoulou-Stinga H, Mataki-Emmanouilidou T, Karida- Kavalioti S, Manios S. Hepatotoxic reactions in children with severe tuberculosis treated with isoniazid-rifampin. Pediatr Infect Dis 1985; 4: 270-3.

  13. Weisiger RA. Isoniazid Hepatotoxicity. [Online] 2007 Jun 21. Available from: URL:http://emedicine.medscape.com/ article/180554-overview

  14. Saukkonen JJ, Cohn DL, Jasmer RM, Schenker S, Jereb JA, Nolan CM, et al; ATS (American Thoracic Society) Hepatotoxicity of Antituberculosis Therapy Subcommittee. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med 2006; 174: 935-52.

  15. Pande JN, Singh SP, Khilnani GC, Khilnani S, Tandon RK. Risk factors for hepatotoxicity from antituberculosis drugs: a case-control study. Thorax 1996; 51: 132-6.

  16. Døssing M, Wilcke JT, Askgaard DS, Nybo B. Liver injury during antituberculosis treatment: an 11-year study. Tuber Lung Dis 1996; 77: 335-40.

  17. Shakya R, Rao BS, Shrestha B. Incidence of hepatotoxicity due to antitubercular medicines and assessment of risk factors. Ann Pharmacother 2004; 38: 1074-9.

  18. Hussain Z, Kar P, Husain SA. Antituberculosis drug-induced hepatitis: risk factors, prevention and management. Indian J Exp Biol 2003; 41: 1226-32.

  19. Singh J, Arora A, Garg PK, Thakur VS, Pande JN, Tandon RK. Antituberculosis treatment-induced hepatotoxicity: role of predictive factors. Postgrad Med J 1995; 71: 359-62.

  20. Ungo JR, Jones D, Ashkin D, Hollender ES, Bernstein D, Albanese AP, et al. Antituberculosis drug-induced hepatotoxicity. The role of hepatitis C virus and the human immunodeficiency virus. Am J Respir Crit Care Med 1998; 157: 1871-6.

  21. Reto Valiente LV, Castillo Vergara J, Pichilingue Reto P, Pichilingue Prieto OA. Hepatotoxicity caused by antituberculosis drugs in pediatrics. Rev Gastroenterol Peru 2005; 25: 362-5.

  22. Guidance for national tuberculosis programs on the management of tuberculosis in children. [Online] 2006. Available from: URL: http://whqlibdoc.who.int/hq/2006/ WHO_HTM_TB_2006.371_eng.pdf Accessed on 18th February 2009




2020     |     www.medigraphic.com